Navigation Links
Sorrento Therapeutics Awarded NIH Grant for MRSA Program
Date:5/21/2010

-money">$5 billion.

About the Sorrento Therapeutics MRSA Program

Sorrento Therapeutics has obtained an exclusive, worldwide license from The Scripps Research Institute (TSRI) to use this novel quorum sensing technology to identify fully human antibodies for the neutralization of Staph-specific signaling peptides that control bacterial virulence. A research group at the Institute has shown that sequestering these signaling peptides, which are integral components of a bacterial communication process called quorum sensing, results in significantly reduced virulence of MRSA in both cellular and animal models. The Company believes the Staph signaling peptide analogs described by TSRI represent a unique opportunity to develop both vaccines and antibody-based immunotherapeutics to combat MRSA.

About Sorrento Therapeutics

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. More information is available at www.sorrentotherapeutics.com. Information on the Company's website or any other website does not constitute a part of this press release.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-lo
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... CARLSBAD, Calif. , June 19, 2013 /PRNewswire/ ... ) today announces a licensing agreement granting Suzhou ... develop and manufacture siRNA therapeutics in ... technology.  Ribo will formulate proprietary siRNA molecules in ... platform designed to address human diseases with high ...
(Date:6/19/2013)... , June 19, 2013 Today ... solutions, introduced the next-generation of its Employer ... allows health plans to provide their employer groups ... health factors, medical and prescription drug claims, network ... (Logo: http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) "Employer ...
(Date:6/19/2013)... INDIANAPOLIS , 19. Juni 2013 ... bekannt, dass mit der Entwicklung von ... bahnbrechender Schritt in der Beschichtung mit ... die Vorteile von biokompatiblem Parylene mit ... effektive Beseitigung schädlicher Mikroorganismen auf beschichteten ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4MedeAnalytics Introduces Next-Generation Employer Group and Individual Business Analytics Solution 2Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2
... the journal Blood found 92 percent reduction in ... ... Patients with a rare,blood disorder called PNH experienced a 92 ... treatment,with Soliris(TM) (eculizumab), according to an analysis of clinical studies,recently ...
... Groundbreaking 2002 ... ... study reveals that,coiling, a minimally invasive procedure to treat aneurysms in ... treatment in those aneurysms considered "untouchable" by the,traditional surgical option. One ...
Cached Medicine Technology:PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 2PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 3PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 4PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 5PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 6PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 7PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials 8New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 2New Study Proves That Minimally Invasive Aneurysm Treatment Yields Successful Long-Term Results 3
(Date:6/19/2013)... Citi Bike has come to New York City in a ... know for sure how many patients will choose to take advantage ... option. In fact, he’s happy about anything that might help ... more convenient for them to visit his office at 133 East ... Medicine at Back and Body Medical and an experienced NYC ...
(Date:6/19/2013)... 19, 2013 According to a June 17, ... Sunburn,” it is not uncommon for a person to suffer ... A person is likely to forget to reapply sunscreen properly ... both dry and itchy. When this occurs, it is essential ... , “Most people do not realize that milk contains proteins, ...
(Date:6/19/2013)... in emergency medicine and trauma surgery have had ... the days immediately after major injuries, including burns. ... their injuries now are at greatest risk from ... known as sepsis or from inflammation-induced multiorgan ... General Hospital (MGH) investigators that measures the movement ...
(Date:6/19/2013)... 2013) In what is believed to be the ... form of hereditary dystonia a movement disorder that ... brain stimulation report good success rates and lasting benefits. ... Disorders Program at Cedars-Sinai Medical Center,s Department of Neurology, ... of Neurosurgery at Beth Israel Deaconess Medical Center in ...
(Date:6/19/2013)... 2013) The results of three important studies have ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... continuous "machine learning" using artificial neural networks (ANNs) may ... advanced brain cancers. Another study in the June ...
Breaking Medicine News(10 mins):Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 2Health News:New York City's Back and Body Medical Welcomes Citi Bike to Midtown Manhattan 3Health News:Skin Care – How to treat Sunburn 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 2Health News:Restoring appropriate movement to immune cells may save seriously burned patients 3Health News:Long-term study reports deep brain stimulation effective for most common hereditary dystonia 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 2Health News:Neurosurgery publishes findings of 3 important studies in June issue 3
... Coalition for,Pulmonary Fibrosis (CPF) announced the appointment of ... has more than 25 years of experience,overseeing all ... in,leadership for non-profit foundations such as the CPF. ... including expanding CPF fundraising,capabilities and driving its overall ...
... Assume Key Management Posts as Senior Vice Presidents, ... (NYSE: AGP ) today announced the hiring ... key management positions: Linda,Whitley-Taylor has been named Executive ... AMERIGROUP as Senior Vice President, Senior,Litigation Counsel; and ...
... Robert A Weinberg is the first recipient of the science ... Georg and Eva Klein. The prize is awarded in person ... 29 January 2008. The prizewinner, who is to be a ... to Karolinska Institutet in Stockholm for two weeks to give ...
... In today,s volatile business,environment, unforeseen market shifts ... product forecasts, sales strategies and,development plans. By ... a high-functioning Competitive Intelligence group,can alert organizations ... warn,them about potential external risks., Competitive ...
... Collaboration with Harvard Medical International Provides ... Vital Global Health Information, BALTIMORE, Jan. 29 ... reach of their groundbreaking MEDEX,360m partnership with the launch ... and leisure travelers., Like the original MEDEX 360m ...
... side by side to equal the width of a human ... for administering medicines and other therapeutic agents to patients. But ... after they discharge their medical payloads has been a major ... months tracking the tiny tubes inside mice, have found some ...
Cached Medicine News:Health News:CPF Appoints Mishka Michon Chief Executive Officer 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 2Health News:AMERIGROUP Names Linda Whitley-Taylor as Executive Vice President, Associate Services 3Health News:Building and Sustaining Impactful Competitive Intelligence Organizations for Pharma 2Health News:MEDEX / Harvard Partnership Now Offers Affordable, New Intelligence to Individual Business & Leisure Travelers 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... a leading provider of immunofluorescence assays, with ... that includes kits for autoimmune diseases, infectious ... conjugates and components. Our Impact IFA Test ... substrates and kit sizes to choose from. ...
... Our breadth of infectious disease ELISA products ... With standard assay protocols for faster integration ... ELISA products provide increased reliability and run-to-run ... antibody detection assays for a wide range ...
Medicine Products: